Market Overview

Will Merck Encroach On Gilead's Harvoni Territory?

Share:
Related MRK
Will Johnson & Johnson's Pharma Segment Pull Up Its Q4 Earnings?
Early Keytruda Results Win Merck An Upgrade
3 Things In Biotech You Should Learn Today: January 20, 2018 (Seeking Alpha)
Related GILD
The Top 10 Value Stocks In The S&P 500
5 Biggest Price Target Changes For Tuesday
Gilead Aims To Take A Giant Lead In The CAR-T Space (Seeking Alpha)

Slingshot Insights recently conducted an interview with Dr. Bruce Bacon, Professor of Internal Medicine at Saint Louis University School of Medicine about the impact that Merck & Co., Inc. (NYSE: MRK)’s Zepatier will have on the HCV market, particularly when it comes to Gilead Sciences, Inc. (NASDAQ: GILD)'s Harvoni and AbbVie Inc (NYSE: ABBV)'s Viekira Pak.

When asked about his impression of Zepatier and its potential impact on the market, Dr. Bacon said he anticipates the drug playing a large role in the future of HCV treatment.

"The cure rates are excellent. It’s basically a genotype 1 and 4 treatment, it's not for 2's and 3’s, but we don’t see a lot of 2’s and 3’s, and we see hardly any 5's and 6's," Dr. Bacon explained. "So, it's pertinent to 80% of the patients that we see."

Related Link: Valeant Had A 58% Chance Of Bankruptcy Last Year

When asked about how much market penetration Zepatier will achieve, Dr. Bacon noted that it's a bit more complicated than simply choosing the treatment that works best in a given situation.

"It's going to be contracting, and it's going to be whether or not Merck has successfully crashed into the contracting that Gilead has already got with insurance companies," he explained. "If Gilead has exclusive contracting with someone, with some company or with some insurance plan, that says for all Hep C you’re going to use Gilead products only and we're going to… give you a drug at a discount for that, it's going to be tough for Merck to cut into that."

Disclosure: the author holds no position in the stocks mentioned.

Latest Ratings for MRK

DateFirmActionFromTo
Jan 2018SunTrust Robinson HumphreyUpgradesHoldBuy
Nov 2017Bank of AmericaReinstatesBuyBuy
Oct 2017BMO CapitalMaintainsOutperform

View More Analyst Ratings for MRK
View the Latest Analyst Ratings

Posted-In: Dr. Bruce Bacon HarvoniAnalyst Color Biotech Health Care Analyst Ratings Interview General

 

Related Articles (GILD + ABBV)

View Comments and Join the Discussion!